Neogenomics stock hits 52-week high at 15.61 USD
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NeoGenomics Inc (NEO)
The NeoGenomics share price today is 15.29, view NASDAQ NEO stock exchange data. Track the latest NeoGenomics share price with real-time updates on NEO stock performance including market cap, day range, 52-week range and dividend yield. Access NEO charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.27
15.90
52 wk Range
5.09
16.17
NEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.2715.90
52 wk Range
5.0916.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NEO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
19.72
Upside
+28.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
8 Buy
4 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 19.72
(+28.99% Upside)
NeoGenomics Inc SWOT Analysis
Strategic Crossroads | Neo Performance Materials faces pivotal decisions as it navigates market challenges and explores strategic alternatives, potentially reshaping its future in advanced materials |
European Expansion | Delve into Neo's new agreement with a major European automotive supplier, signaling growth potential in the electric vehicle and green technology sectors |
Market Dynamics | Explore the complexities of the rare earths market, including geopolitical factors, supply chain challenges, and Neo's positioning amidst industry volatility |
Financial Outlook | Analysts project positive earnings for Neo, with Stifel setting a C$13.00 price target. The company's strategic review remains the primary value drive |
NeoGenomics Inc Earnings Call Summary for Q2/2026
- NeoGenomics Q2 2026 EPS of $0.05 beat estimates by $0.02; revenue of $202M topped forecasts by $5M, rising 11% YoY on clinical testing strength.
- NGS revenue surged 26% YoY; company raised FY2026 revenue guidance to $802M-$806M and adjusted EBITDA outlook to $56M-$58M from prior ranges.
- Clinical revenue grew 14% with 12% price increase from improved test mix; adjusted gross margin expanded 260bps to 48.1% as profitability improved.
- Management expects mid-20s NGS growth for FY2026, low-teens clinical growth, and Medicare reimbursement for two RaDaR ST indications by year-end.
- Pharma segment fell 26% but deemed 'opportunistic'; CEO emphasized clinical business as core growth driver with expansion into solid tumor testing markets.
Last Updated: 29-07-2026, 03:16 am
Read Full TranscriptEarnings
Latest Release
28-07-2026
EPS / Forecast
0.05 / 0.03
Revenue / Forecast
202M / 196.99M
Compare NEO to Peers and Sector
Metrics to compare | NEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −37.9x | −10.4x | −0.3x | |
PEG Ratio | −0.74 | −0.07 | 0.00 | |
Price/Book | 2.5x | 3.9x | 2.6x | |
Price / LTM Sales | 2.6x | 1.9x | 3.0x | |
Upside (Analyst Target) | 24.3% | 20.3% | 56.7% | |
Fair Value Upside | Unlock | 6.7% | 9.4% | Unlock |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the NeoGenomics (NEO) Share Price Today?
The NeoGenomics share price today is 15.29.
What is the current NeoGenomics (NEO) share price and day range?
As of 01-08-2026, the NeoGenomics share price is 15.29, with a previous close of 15.88. The share price has ranged from 15.27 to 15.90 today, while the 52-week range spans from 5.09 to 16.17.
What Is the NeoGenomics Market Cap?
As of today, NeoGenomics market cap is 2.04B.
What Is the NeoGenomics (NEO) Share Price Target?
The average 12-month share price target for NeoGenomics is 19.72, with a high estimate of 35 and a low estimate of 16. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +28.99% Upside potential.
What Is NeoGenomics's Earnings Per Share (TTM)?
The NeoGenomics EPS (TTM) is -0.40.
When Is the Next NeoGenomics Earnings Date?
NeoGenomics will release its next earnings report on 10-11-2026.
From a Technical Analysis Perspective, Is NEO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does NeoGenomics Trade On?
NeoGenomics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for NeoGenomics?
The stock symbol for NeoGenomics is "NEO."
How Many Times Has NeoGenomics Stock Split?
NeoGenomics has split 2 times.
How Many Employees Does NeoGenomics Have?
NeoGenomics has 2500 employees.
What Is the NEO Premarket Price?
NEO's last pre-market stock price is 15.10. The pre-market share volume is 7,470.00, and the stock has changed by -0.78, or -4.91%.
What Is the NEO After Hours Price?
NEO's last after hours stock price is 15.50, the stock has changed by 0.21, or 1.37%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.